```json
{
"content": [
{
"type": "list",
"title": "Growth Drivers",
"items": [
{
"text": "The rising prevalence of cardiovascular diseases (CVD) is fueling demand for Isosorbide Mononitrate Injection, with global CVD cases projected to increase by 20% by 2030, directly expanding the patient pool and market size.",
"level": 1
},
{
"text": "Hospitalization rates for acute coronary syndromes are climbing, particularly in emerging markets like India and Brazil, where healthcare infrastructure investments are driving adoption of intravenous therapies, bolstering the Isosorbide Mononitrate Injection market growth forecast.",
"level": 1
}
]
},
{
"type": "list",
"title": "Restraints",
"items": [
{
"text": "The availability of cost-effective generic alternatives is constraining market expansion, as price-sensitive healthcare providers in developed regions shift toward cheaper options, limiting the Isosorbide Mononitrate Injection market size growth.",
"level": 1
},
{
"text": "Stringent regulatory requirements in the EU for cardiovascular drug approvals, including additional clinical trial mandates, are delaying product launches and raising compliance costs for manufacturers.",
"level": 1
}
]
},
{
"type": "list",
"title": "Opportunities",
"items": [
{
"text": "Advancements in IV formulation technologies, such as extended-release injectables, present unmet needs in hospitals, offering differentiation and higher pricing potential for market leaders.",
"level": 1
},
{
"text": "Strategic collaborations between pharmaceutical firms and telehealth platforms to streamline post-discharge care for CVD patients could enhance treatment adherence, indirectly boosting demand for injectable therapies.",
"level": 1
}
]
},
{
"type": "list",
"title": "Challenges",
"items": [
{
"text": "Patent expirations for key Isosorbide Mononitrate brands in 2024–2025 are expected to trigger a 15–20% price decline in the Isosorbide Mononitrate Injection market, intensifying competition from generic entrants.",
"level": 1
},
{
"text": "Supply chain disruptions for active pharmaceutical ingredients (APIs) due to geopolitical tensions in
